| # Scientific Scope |
|
|
| ## What This Resource Does |
|
|
| This benchmark integrates evidence-synthesis scores, target tractability, omics/pathway recurrence, ChEMBL compound activity, simple drug-likeness heuristics, Human Protein Atlas cell-type context, stem-cell validation mappings, and knowledge-graph exports for Parkinson's disease target-to-intervention research. |
|
|
| ## What It Does Not Do |
|
|
| It does not prove that any drug, supplement, diet, or lifestyle change prevents or cures Parkinson's disease. It does not recommend off-label clinical use. It does not replace systematic review, pharmacology review, toxicology, cellular validation, animal studies, or clinical trials. |
|
|
| ## Appropriate Uses |
|
|
| - benchmarking target-prioritisation methods; |
| - identifying candidate targets for iPSC-derived dopaminergic-neuron experiments; |
| - comparing drug-repurposing heuristics; |
| - teaching translational bioinformatics workflows; |
| - generating hypotheses for independent validation. |
|
|
| ## Highest-Priority Validation Direction |
|
|
| The most defensible next experiments are target-module validation studies that connect reproducible PD biology to feasible assays: |
|
|
| - lysosome/autophagy and GBA1/LRRK2 biology in patient-derived dopaminergic neurons; |
| - mitochondrial stress and PINK1/Parkin-axis readouts; |
| - alpha-synuclein aggregation and clearance assays; |
| - inflammatory co-culture systems for microglial or cytokine-mediated effects; |
| - metabolic/GLP-1 signalling assays as disease-modification hypotheses, not clinical recommendations. |
|
|
